Core Insights - Aethlon Medical, Inc. reported financial results for its fiscal second quarter ended September 30, 2025, highlighting clinical progress and cost reductions [1][12][13]. Clinical and Corporate Update - The company is advancing its clinical initiatives, particularly in cancer treatment, and has resolved Nasdaq compliance matters, maintaining its listing [2][16]. - Recruitment for the second cohort of the Australian oncology trial of the Hemopurifier® has begun, allowing patients to receive combination therapies with Pembrolizumab or Nivolumab [3][9]. - The primary endpoint of the study is safety, with plans to enroll approximately 9 to 18 participants [9]. Scientific Developments - Analysis of extracellular vesicles (EVs) from patients in the first cohort showed decreases in large EVs after Hemopurifier treatment, which are implicated in cancer progression [4]. - Improvements in laboratory ratios associated with immunotherapy responses were observed in at least two participants following treatment [6]. - Ongoing collaboration with UCSF focuses on Long COVID research, with a manuscript in preparation for peer-reviewed publication [10]. Financial Performance - Operating expenses decreased by 48% to approximately $1.5 million for the quarter, down from $2.9 million in the same period in 2024 [12][14]. - The operating loss for the quarter decreased to $1.5 million compared to $2.8 million in the prior-year period [15]. - As of September 30, 2025, Aethlon had a cash balance of approximately $5.8 million [13]. Operational Achievements - The company has initiated an evaluation of the Hemopurifier's compatibility with a simplified blood treatment system, which could enhance treatment delivery in oncology units [11]. - Significant cost management efforts have led to reductions in payroll, general and administrative expenses, and professional fees [17].

Core Insights - Aethlon Medical, Inc. has provided updates on its ongoing oncology clinical trial in Australia, focusing on the Hemopurifier's effects on cancer patients not responding to anti-PD-1 therapy [3][4][11] Clinical Trial Observations - The initial cohort of three patients showed promising changes in extracellular vesicles (EVs), microRNAs, and lymphocyte counts after a single treatment with the Hemopurifier [4][5] - Changes in EV and microRNA levels typically returned to baseline within 1 to 3 weeks post-treatment [6] - Two of the three participants exhibited decreases in large EVs, which are implicated in cancer metastasis and immune response inhibition [10] Hemopurifier Mechanism - The Hemopurifier is designed to remove enveloped viruses and tumor-derived EVs from circulation, potentially aiding in cancer treatment by targeting mannose-rich surfaces on EVs and viral proteins [9][11] - The device has received U.S. Food and Drug Administration Breakthrough Device Designation for treating advanced or metastatic cancer and life-threatening viruses [11] Patient Response and Data Limitations - Increases in total T cell numbers and specific T cell subsets were noted in participants following treatment, although the data is limited due to the small sample size [10] - The study's preliminary nature means that no definitive conclusions can be drawn regarding the clinical efficacy of the Hemopurifier [8][10]

Core Viewpoint - Aethlon Medical, Inc. is set to release its financial results for the fiscal first quarter ending June 30, 2025, on August 13, 2025, at 4:15 p.m. ET, followed by a conference call to discuss these results and recent corporate developments [1][2]. Financial Results Announcement - The financial results will be announced on August 13, 2025, at 4:15 p.m. ET [1]. - A conference call will take place on the same day at 4:30 p.m. ET to review the financial results and recent developments [2]. Conference Call Details - Interested parties can register for the conference call online, and registered participants will receive a dial-in number [2]. - For those without internet access, a toll-free number is available for participation [3]. Replay Information - A replay of the conference call will be available approximately one hour after the call and can be accessed until September 13, 2025 [4]. Product Overview - The Aethlon Hemopurifier is an investigational medical device designed to remove enveloped viruses and tumor-derived extracellular vesicles from circulation [4]. - The device utilizes a novel platform that combines plasma separation, size exclusion, and affinity binding to target pathogenic elements in biological fluids [6]. Regulatory Designation - The Hemopurifier has received U.S. Food and Drug Administration Breakthrough Device Designation for treating advanced or metastatic cancer and life-threatening viruses [5]. Company Background - Aethlon Medical, Inc. is a clinical-stage medical device company based in San Diego, California, focusing on oncology and infectious disease [6].

Core Insights - Aethlon Medical, Inc. has made significant progress in its Hemopurifier® cancer trial, having treated three patients and received regulatory approval in India for a similar study [1][9][11] - The company has successfully reduced operating expenses by approximately 26% year-over-year, positioning itself for sustained focus on clinical and regulatory goals [14][16] - Preliminary data from the ongoing trials is expected to provide insights into the efficacy of the Hemopurifier in treating solid tumors and potentially Long COVID [4][10][13] Clinical Progress in Cancer Trial - The first three participants in the Hemopurifier trial completed treatment without complications, and safety follow-ups have been conducted [3][4] - An independent Data Safety Monitoring Board (DSMB) will review safety data and recommend advancement to the next treatment cohort [4] - The trial protocol has been amended to include patients receiving combination therapies with Pembrolizumab or Nivolumab, reflecting current treatment practices [5][6] Regulatory Approval India - Aethlon received approval from India's CDSCO to initiate a similar trial at Medanta Medicity Hospital, following necessary ethical clearances [9] Preclinical Study Supports Broader Applications - A preclinical study demonstrated that the Hemopurifier can remove 98.5% of platelet-derived extracellular vesicles (PD-EVs) from human plasma, indicating potential applications in various diseases [10][11] Scientific Collaboration in Long COVID Research - Aethlon is collaborating with UCSF to investigate the Hemopurifier's potential in treating Long COVID, with findings to be presented at an upcoming symposium [13] Operational Achievements - The company streamlined operations, resulting in a significant reduction in operating expenses, which decreased from approximately $12.6 million in fiscal 2024 to $9.3 million in fiscal 2025 [16][20] Financial Results for the Fiscal Fourth Quarter Ended March 31, 2025 - As of March 31, 2025, Aethlon had a cash balance of approximately $5.5 million [15] - The operating loss for the fiscal year ended March 31, 2025, was $9.3 million, down from $12.6 million the previous year [20][32]

Core Viewpoint - Aethlon Medical, Inc. is set to release its financial results for the fiscal fourth quarter ended March 31, 2025, on June 26, 2025, at 4:15 p.m. ET [1] Financial Results Announcement - The financial results will be followed by a conference call hosted by management on June 26, 2025, at 4:30 p.m. ET to discuss the results and recent corporate developments [2] - Interested parties can register for the conference call online, and registered participants will receive their dial-in number upon registration [2] Conference Call Details - For those without internet access, a toll-free participant dial-in number is available at 1-844-836-8741, with an international dial-in option at 1-412-317-5442 [3] - A replay of the call will be accessible approximately one hour after the call ends and will be available until July 26, 2025 [4] Company Overview - Aethlon Medical focuses on developing the Hemopurifier, an immunotherapeutic device aimed at treating cancer and life-threatening viral infections [5] - The Hemopurifier has shown promise in human studies for removing life-threatening viruses and harmful exosomes, which may contribute to immune suppression and cancer metastasis [5] - The device has received FDA Breakthrough Device designation for treating advanced or metastatic cancer and life-threatening viruses not addressed by approved therapies [5]

Core Insights - Aethlon Medical, Inc. is presenting research on the Hemopurifier® device's ability to bind extracellular vesicles (EVs) in Long COVID samples at an upcoming symposium [1][6] - Long COVID affects an estimated 44 to 48 million people in the U.S., with a significant economic burden projected at $2 billion for those experiencing symptoms for a year [2] - The Hemopurifier is designed to remove harmful EVs from the blood, which are implicated in the pathogenesis of Long COVID [4][8] Company Overview - Aethlon Medical focuses on developing the Hemopurifier, an investigational device aimed at treating cancer and life-threatening infectious diseases [8] - The Hemopurifier has shown efficacy in removing life-threatening viruses and harmful EVs in pre-clinical studies [8] - The device has received FDA Breakthrough Device designation for treating advanced or metastatic cancer and life-threatening viruses [10] Research Details - The research presented will evaluate the binding of EVs from Long COVID patients to the Hemopurifier's affinity resin, which targets the sugar mannose [5][6] - The study involves collaboration with the University of California San Francisco Medical Center Long COVID clinic [5] - The poster presentation is scheduled for August 12, 2025, and will be available on Aethlon's corporate website afterward [6][7]

Core Insights - Aethlon Medical, Inc. announced the publication of a pre-clinical ex vivo study demonstrating the effectiveness of its Hemopurifier in removing platelet-derived extracellular vesicles (PD-EVs) from plasma, which supports ongoing oncology clinical trials in Australia [1][4][6] Group 1: Study Findings - The study showed a 98.5% removal of PD-EVs from 200 milliliters of healthy human plasma, simulating a 4-hour treatment session with the Hemopurifier [3][4] - The results indicate the potential of the Hemopurifier to address various diseases where PD-EVs are implicated, including cancer and other serious conditions [5][6] Group 2: Clinical Implications - The findings are expected to enhance the ongoing oncology clinical trial in Australia, where the focus will be on PD-EV removal in enrolled subjects [4][5] - The Hemopurifier is recognized as a Breakthrough Device by the FDA, aimed at treating advanced or metastatic cancer and life-threatening viral infections [6] Group 3: Future Directions - The company plans to submit the study findings for peer review and further investigate PD-EV removal in plasma samples from various diseases [5] - There is potential for the Hemopurifier to serve multiple therapeutic indications beyond oncology, suggesting a "pipeline within a device" concept [5]

Core Insights - Aethlon Medical's Hemopurifier® shows expanded therapeutic potential beyond virology and oncology, particularly in organ transplantation [1][2] - A preclinical study published in Transplant Immunology demonstrates the Hemopurifier's ability to remove extracellular vesicles (EVs) and microRNAs from discarded donor kidneys, which may improve kidney function post-transplant [1][2] - The company is currently focused on oncology trials in Australia and India, but the new data suggests a broader application for the Hemopurifier in organ preservation [2][3] Company Overview - Aethlon Medical is a therapeutic company developing the Hemopurifier, designed to combat cancer, life-threatening viral infections, and for organ transplantation [3] - The Hemopurifier has received FDA Breakthrough Device designation for treating advanced or metastatic cancer and life-threatening viruses [3] Research Findings - The preclinical study indicates significant reductions in EVs and microRNAs associated with renal dysfunction when using the Hemopurifier on perfusion fluid from discarded kidneys [2] - The study supports the hypothesis that EVs and microRNAs contribute to complications in kidney transplantation, such as delayed function and organ rejection [2] Future Directions - Further evaluation of the Hemopurifier's integration into machine perfusion circuits for discarded kidneys is necessary, with plans for clinical trials to assess its efficacy [2][3] - The technology could potentially enhance existing organ preservation methods, indicating a "pipeline within a device" for future therapeutic applications [2]